CLS vs. HALO
CLS (Celestica Inc.) and HALO (Halozyme Therapeutics, Inc.) are both stocks. CLS operates in Electronic Components (Technology), while HALO operates in Biotechnology (Healthcare). Over the past 10 years, CLS returned 43.71%/yr vs 22.84%/yr for HALO. At a 0.24 correlation, their price movements are largely independent.
Performance
CLS vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLS achieves a 32.99% return, which is significantly higher than HALO's 3.27% return. Over the past 10 years, CLS has outperformed HALO with an annualized return of 43.71%, while HALO has yielded a comparatively lower 22.84% annualized return.
CLS
- 1D
- 1.88%
- 1M
- 3.02%
- YTD
- 32.99%
- 6M
- 28.26%
- 1Y
- 213.67%
- 3Y*
- 207.28%
- 5Y*
- 116.26%
- 10Y*
- 43.71%
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
CLS vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 32.99% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -11.56% |
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
Correlation
The correlation between CLS and HALO is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.10 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Mar 16, 2004 | 0.24 |
The correlation between CLS and HALO shifts across timeframes, from 0.10 (1 year) to 0.24 (all time), reflecting how their relationship changes across market environments.
Fundamentals
CLS:
$45.48B
HALO:
$8.54B
CLS:
$8.28
HALO:
$2.87
CLS:
47.45
HALO:
24.26
CLS:
0.64
HALO:
2.74
CLS:
3.30
HALO:
5.61
CLS:
21.68
HALO:
38.88
CLS:
$13.81B
HALO:
$1.51B
CLS:
$1.60B
HALO:
$1.23B
CLS:
$1.32B
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLS vs. HALO — Risk / Return Rank
CLS
HALO
CLS vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLS | HALO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.87 | ||
| Sortino ratioReturn per unit of downside risk | +1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.17 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 6.91 | 1.14 | +5.77 |
| Martin ratioReturn relative to average drawdown | 16.83 | 2.16 | +14.67 |
Loading charts...
Drawdowns
CLS vs. HALO - Drawdown Comparison
The maximum CLS drawdown since its inception was -96.93%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for CLS and HALO.
Loading charts...
Drawdown Indicators
| CLS | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.93% | -74.26% | -22.67% |
Max Drawdown (1Y)Largest decline over 1 year | -29.24% | -24.13% | -5.11% |
Max Drawdown (3Y)Largest decline over 3 years | -53.96% | -33.92% | -20.04% |
Max Drawdown (5Y)Largest decline over 5 years | -53.96% | -49.06% | -4.90% |
Max Drawdown (10Y)Largest decline over 10 years | -80.60% | -49.06% | -31.54% |
Current DrawdownCurrent decline from peak | -16.78% | -14.44% | -2.34% |
Average DrawdownAverage peak-to-trough decline | -73.31% | -31.88% | -41.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.98% | 12.73% | -0.75% |
Volatility
CLS vs. HALO - Volatility Comparison
Celestica Inc. (CLS) has a higher volatility of 27.54% compared to Halozyme Therapeutics, Inc. (HALO) at 8.94%. This indicates that CLS's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLS | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.54% | 8.94% | +18.60% |
Volatility (6M)Calculated over the trailing 6-month period | 55.42% | 24.02% | +31.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 72.65% | 30.20% | +42.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.70% | 39.42% | +18.28% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.97% | 42.88% | +7.09% |
Dividends
CLS vs. HALO - Dividend Comparison
Neither CLS nor HALO has paid dividends to shareholders.
Financials
CLS vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Celestica Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLS vs. HALO - Profitability Comparison
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
CLS and HALO have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.54%) compared to HALO (8.94%). In terms of maximum drawdown, CLS dropped -96.93% vs HALO's -74.26%.
CLS currently has the higher Sharpe Ratio (2.78 vs 0.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLS and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer